MEDICOX Co., Ltd. (KOSDAQ:054180)
South Korea · Delayed Price · Currency is KRW 2,295.00
-270.00 (-10.53%)
At close: Jul 2, 2025
MEDICOX Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 28,161 | 30,611 | 26,875 | 20,296 | 17,449 |
| 28,161 | 30,611 | 26,875 | 20,296 | 17,449 | |
Revenue Growth (YoY) | -8.00% | 13.90% | 32.42% | 16.32% | 7.78% |
Cost of Revenue | 26,048 | 28,627 | 25,022 | 19,801 | 17,015 |
Gross Profit | 2,113 | 1,984 | 1,853 | 494.97 | 433.65 |
Selling, General & Admin | 7,394 | 11,014 | 10,776 | 10,532 | 8,927 |
Research & Development | - | 2.2 | 2.4 | 2.4 | 2.4 |
Amortization of Goodwill & Intangibles | 8.31 | 8.36 | 3.53 | 48.31 | 2.41 |
Other Operating Expenses | 91.01 | 45.77 | 81.13 | 53.56 | 47.84 |
Operating Expenses | 8,030 | 12,775 | 14,764 | 14,368 | 10,621 |
Operating Income | -5,917 | -10,791 | -12,911 | -13,873 | -10,187 |
Interest Expense | -1,452 | -2,309 | -3,948 | -2,680 | -3,586 |
Interest & Investment Income | 125.66 | 267.77 | 473.77 | 278.31 | 83.59 |
Earnings From Equity Investments | -2,244 | -2,374 | -1,284 | 52.84 | -1,605 |
Currency Exchange Gain (Loss) | -0.67 | 0.08 | -0.39 | -1.15 | -0.19 |
Other Non Operating Income (Expenses) | 769.1 | 1,046 | -2,615 | -14,301 | -966.08 |
EBT Excluding Unusual Items | -8,719 | -14,159 | -20,285 | -30,524 | -16,261 |
Gain (Loss) on Sale of Investments | -2,127 | -4,154 | -11,837 | -8,923 | -7,663 |
Gain (Loss) on Sale of Assets | -837.46 | -3.43 | 967.91 | 3.83 | 10.47 |
Asset Writedown | - | -2,824 | -43.28 | -4,292 | - |
Other Unusual Items | -82.13 | -354.95 | 45.06 | 1,931 | -24.03 |
Pretax Income | -11,766 | -21,497 | -31,152 | -41,804 | -23,938 |
Income Tax Expense | 129.76 | -72.46 | - | - | - |
Earnings From Continuing Operations | -11,895 | -21,424 | -31,152 | -41,804 | -23,938 |
Earnings From Discontinued Operations | - | -10.65 | -3,274 | -814.32 | - |
Net Income to Company | -11,895 | -21,435 | -34,427 | -42,619 | -23,938 |
Minority Interest in Earnings | - | - | - | - | 3.15 |
Net Income | -11,895 | -21,435 | -34,427 | -42,619 | -23,935 |
Net Income to Common | -11,895 | -21,435 | -34,427 | -42,619 | -23,935 |
Shares Outstanding (Basic) | 5 | 4 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 5 | 4 | 2 | 1 | 1 |
Shares Change (YoY) | 40.36% | 98.66% | 37.16% | 59.58% | 90.89% |
EPS (Basic) | -2209.00 | -5587.00 | -17826.17 | -30267.49 | -27125.52 |
EPS (Diluted) | -2209.00 | -5587.00 | -17826.17 | -30267.49 | -27125.52 |
Free Cash Flow | -4,206 | -7,000 | -9,340 | -12,855 | -8,807 |
Free Cash Flow Per Share | -781.15 | -1824.53 | -4836.04 | -9129.83 | -9980.78 |
Gross Margin | 7.51% | 6.48% | 6.90% | 2.44% | 2.48% |
Operating Margin | -21.01% | -35.25% | -48.04% | -68.35% | -58.38% |
Profit Margin | -42.24% | -70.02% | -128.10% | -209.99% | -137.17% |
Free Cash Flow Margin | -14.94% | -22.87% | -34.75% | -63.34% | -50.47% |
EBITDA | -4,187 | -8,688 | -9,940 | -10,602 | -7,978 |
EBITDA Margin | -14.87% | -28.38% | -36.98% | -52.23% | -45.72% |
D&A For EBITDA | 1,729 | 2,103 | 2,971 | 3,272 | 2,209 |
EBIT | -5,917 | -10,791 | -12,911 | -13,873 | -10,187 |
EBIT Margin | -21.01% | -35.25% | -48.04% | -68.35% | -58.38% |
Advertising Expenses | 94.81 | 208.38 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.